WO2006020208A3 - Therapeutic composition whit a botulinum neurotoxin - Google Patents

Therapeutic composition whit a botulinum neurotoxin Download PDF

Info

Publication number
WO2006020208A3
WO2006020208A3 PCT/US2005/025408 US2005025408W WO2006020208A3 WO 2006020208 A3 WO2006020208 A3 WO 2006020208A3 US 2005025408 W US2005025408 W US 2005025408W WO 2006020208 A3 WO2006020208 A3 WO 2006020208A3
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum neurotoxin
whit
therapeutic composition
neurotoxin
botulinum
Prior art date
Application number
PCT/US2005/025408
Other languages
French (fr)
Other versions
WO2006020208A2 (en
Inventor
Harold Victor Taylor
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Harold Victor Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35355516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006020208(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2578250A priority Critical patent/CA2578250C/en
Priority to MX2007000794A priority patent/MX2007000794A/en
Priority to CN2005800282064A priority patent/CN101005853B/en
Application filed by Merz Pharma Gmbh & Co Kgaa, Harold Victor Taylor filed Critical Merz Pharma Gmbh & Co Kgaa
Priority to AU2005274822A priority patent/AU2005274822B2/en
Priority to BRPI0513850-7A priority patent/BRPI0513850A/en
Priority to EA200700213A priority patent/EA011652B1/en
Priority to EP05765454.3A priority patent/EP1786459B1/en
Priority to JP2007523628A priority patent/JP4907530B2/en
Publication of WO2006020208A2 publication Critical patent/WO2006020208A2/en
Publication of WO2006020208A3 publication Critical patent/WO2006020208A3/en
Priority to IL180771A priority patent/IL180771A/en
Priority to NO20071043A priority patent/NO20071043L/en
Priority to HK07113262.7A priority patent/HK1107670A1/en
Priority to IL219897A priority patent/IL219897A0/en
Priority to IL225848A priority patent/IL225848A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.
PCT/US2005/025408 2004-07-26 2005-07-19 Therapeutic composition whit a botulinum neurotoxin WO2006020208A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2007523628A JP4907530B2 (en) 2004-07-26 2005-07-19 A therapeutic composition comprising a botulinum neurotoxin
BRPI0513850-7A BRPI0513850A (en) 2004-07-26 2005-07-19 therapeutic composition with a botulically neurotoxin
MX2007000794A MX2007000794A (en) 2004-07-26 2005-07-19 Therapeutic composition whit a botulinum neurotoxin.
CN2005800282064A CN101005853B (en) 2004-07-26 2005-07-19 Therapeutic composition with a botulinum neurotoxin
EP05765454.3A EP1786459B1 (en) 2004-07-26 2005-07-19 Therapeutic composition whit a botulinum neurotoxin
AU2005274822A AU2005274822B2 (en) 2004-07-26 2005-07-19 Therapeutic composition with a botulinum neurotoxin
EA200700213A EA011652B1 (en) 2004-07-26 2005-07-19 Therapeutic composition whit a botulinum neurotoxin
CA2578250A CA2578250C (en) 2004-07-26 2005-07-19 Therapeutic composition with a botulinum neurotoxin
IL180771A IL180771A (en) 2004-07-26 2007-01-17 Method for stabilising botulinum neurotoxin, use thereof and pharmaceutical compositions and preparations comprising a botulinum neurotoxin and hyaluronic acid
NO20071043A NO20071043L (en) 2004-07-26 2007-02-23 Therapeutic preparation with a Botulinum neurotoxin
HK07113262.7A HK1107670A1 (en) 2004-07-26 2007-12-05 Therapeutic composition with a botulinum neurotoxin
IL219897A IL219897A0 (en) 2004-07-26 2012-05-20 Therapeutic composition with a botulinum neurotoxin
IL225848A IL225848A0 (en) 2004-07-26 2013-04-18 Therapeutic composition with a botulinum neurotoxin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119604P 2004-07-26 2004-07-26
US60/591,196 2004-07-26

Publications (2)

Publication Number Publication Date
WO2006020208A2 WO2006020208A2 (en) 2006-02-23
WO2006020208A3 true WO2006020208A3 (en) 2006-06-01

Family

ID=35355516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025408 WO2006020208A2 (en) 2004-07-26 2005-07-19 Therapeutic composition whit a botulinum neurotoxin

Country Status (17)

Country Link
US (6) US7879341B2 (en)
EP (3) EP2266600B1 (en)
JP (3) JP4907530B2 (en)
KR (3) KR100852824B1 (en)
CN (2) CN101005853B (en)
AU (1) AU2005274822B2 (en)
BR (1) BRPI0513850A (en)
CA (2) CA2799413A1 (en)
EA (1) EA011652B1 (en)
EC (1) ECSP077197A (en)
ES (1) ES2479515T3 (en)
HK (1) HK1107670A1 (en)
IL (3) IL180771A (en)
MX (1) MX2007000794A (en)
NO (1) NO20071043L (en)
WO (1) WO2006020208A2 (en)
ZA (1) ZA200700433B (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
EP2364734B1 (en) * 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
KR101284710B1 (en) * 2004-03-03 2013-07-23 레반스 테라퓨틱스, 아이엔씨. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (en) * 2004-03-03 2011-12-07 雷文斯治疗公司 Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2799413A1 (en) * 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
EP1856139B1 (en) 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
BRPI0608249A2 (en) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulation, method for topical application and kit for transdermal botulinum toxin delivery
JP5368793B2 (en) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル Compositions and methods for making and using nanoemulsions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JP4944896B2 (en) * 2005-11-17 2012-06-06 ルバンス セラピュティックス インク． Compositions and methods for topical application and transdermal delivery of botulinum toxin comprising reduced non-toxin proteins
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
TR201901443T4 (en) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemulsions.
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US20080063732A1 (en) * 2006-07-31 2008-03-13 Hantash Basil M Method of increasing the efficacy of neurotoxin
JP5345532B2 (en) * 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Drugs for LCT poisoning
BRPI0719732A2 (en) 2006-12-01 2017-05-16 Anterios Inc peptide nanoparticles and uses thereof
EP2494958A1 (en) * 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
JP2010514779A (en) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． Transport molecules using reverse sequence HIV-TAT polypeptides
BRPI0720730A2 (en) * 2006-12-29 2014-04-08 Revance Therapeutics Inc TOPICAL APPLICATION COMPOSITIONS AND METHODS AND TRANSDERMAL RELEASE OF BOTULINIC TOXINS STABILIZED WITH HIV-TAT-DERIVED POLYPEPTIDE FRAGMENTS.
ES2660906T3 (en) 2007-05-31 2018-03-26 Anterios, Inc. Nucleic acid nanoparticles and uses thereof
EP2048156A1 (en) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
CA2686642A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
CA2690773C (en) * 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
DE102007038015A1 (en) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Use of a neurotoxin
SI2198007T1 (en) * 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids a and b
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR20090124421A (en) 2008-05-30 2009-12-03 현대자동차주식회사 Parking brake device for automatic transmission
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
WO2010090677A1 (en) * 2008-12-10 2010-08-12 Allergan, Inc. Clostridial toxin pharmaceutical compositions
SG172812A1 (en) 2008-12-31 2011-08-29 Revance Therapeutics Inc Injectable botulinum toxin formulations
JP5688031B2 (en) 2009-01-07 2015-03-25 ロバート ジョン ペトレラ， Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
AU2010214834B2 (en) * 2009-02-19 2016-04-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
KR102328155B1 (en) * 2009-06-25 2021-11-17 레반스 테라퓨틱스, 아이엔씨. Albumin-free botulinum toxin formulations
ES2693705T3 (en) 2009-07-02 2018-12-13 Merz Pharma Gmbh & Co. Kgaa Neurotoxins that show reduced biological activity
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2013545504A (en) * 2010-10-06 2013-12-26 アラーガン、インコーポレイテッド System for storage and subsequent handling of botulinum toxin
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
WO2012103415A1 (en) * 2011-01-28 2012-08-02 Allergan, Inc. Dosage regimen for the treatment of multiple disorders with botulinum toxins
WO2013068476A1 (en) 2011-11-09 2013-05-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
US10980865B2 (en) * 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
US10894062B2 (en) 2012-08-10 2021-01-19 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
DK2948174T3 (en) 2013-01-28 2019-12-02 Univ New York Methods of treatment using atoxic neurotoxin derivatives
KR20140147950A (en) * 2013-06-20 2014-12-31 서울대학교산학협력단 Composition comprising filler and botulinum toxin for improving skin wrinkle, ageing or treating neuromuscular disease
LT3014267T (en) 2013-06-28 2018-12-10 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
KR101339349B1 (en) * 2013-08-02 2013-12-09 주식회사 대웅 Methods for preparing botulinum toxin
WO2015024503A1 (en) * 2013-08-21 2015-02-26 The Hong Kong Polytechnic University Engineering clostridia neurotoxins with elevated catalytic activity
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CA2969463A1 (en) 2014-12-09 2016-06-16 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
AU2015367329B2 (en) 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
US11969461B2 (en) * 2016-03-02 2024-04-30 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
KR102423739B1 (en) * 2016-05-27 2022-07-21 입센 바이오팜 리미티드 Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
JP7217700B2 (en) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド Stabilized non-protein Clostridial toxin composition
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
KR102487144B1 (en) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 Transdermal delivery of large substances
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
IL304733B1 (en) 2017-03-24 2024-04-01 Merz Pharma Gmbh & Co Kgaa Improved use of botulinum neurotoxin in the treatment of sialorrhea
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
AU2018290765A1 (en) * 2017-06-26 2020-01-23 Bonti, Inc. Clostridial neurotoxin formulations and use
ES2930237T3 (en) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa New recombinant botulinum neurotoxins with longer duration of effects
KR20190038292A (en) 2017-09-29 2019-04-08 한국프라임제약주식회사 A novel botulinum toxin composition having a prolonged period of action
WO2019081022A1 (en) 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019101308A1 (en) 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
KR102274232B1 (en) 2018-08-28 2021-07-08 성균관대학교산학협력단 A composition comprising neuro-targeted proteins
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20210393748A1 (en) 2018-10-02 2021-12-23 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for treating lipoedema
JP2022521237A (en) 2019-02-21 2022-04-06 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン New uses of botulinum neurotoxin for the treatment of tremor
US11202753B1 (en) 2020-03-06 2021-12-21 Aquavit Pharmaceuticals, Inc. Systems and methods for generating immune responses in subjects using microchannel delivery devices
CA3177835A1 (en) 2020-06-05 2021-12-09 Susanna ROLL High dose and low volume botulinum toxin treatment of facial wrinkles
KR20230007129A (en) 2021-07-05 2023-01-12 주식회사 파마리서치바이오 A method for purifying clostridium botulinum toxin complex
KR20230009178A (en) 2021-07-08 2023-01-17 주식회사 파마리서치바이오 A method for purifying clostridium botulinum neurotoxin with reduced non-toxic proteins
WO2023085849A1 (en) * 2021-11-15 2023-05-19 (주)메디톡스 Botulinum neurotoxin composition
TW202400122A (en) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 Use of botulinum toxin for reduction of skin pore size and/or sebum production, and method for reduction of skin pore size and/or sebum production
KR102551301B1 (en) 2022-10-28 2023-07-03 주식회사 파마리서치바이오 Stable liquid formulation comprising Botulinum Toxin

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351162A1 (en) * 1988-07-11 1990-01-17 Albright & Wilson Limited Stabilised enzyme dispersion
JPH034791A (en) * 1989-05-30 1991-01-10 Kanebo Ltd Stabilization of enzyme
WO1997027841A1 (en) * 1996-01-31 1997-08-07 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
WO2000015245A2 (en) * 1998-09-11 2000-03-23 Elan Pharmaceuticals, Inc. Stable liquid formulations of botulinum toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2004060384A2 (en) * 2002-12-20 2004-07-22 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW14486A1 (en) 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
JPH03479A (en) 1989-05-25 1991-01-07 Hitachi Ltd Equipment and method for plasma welding
JP3504721B2 (en) 1994-05-09 2004-03-08 エアバックス インターナショナル リミティド Woven airbag
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
DE19925739A1 (en) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
PT1253932E (en) 2000-02-08 2005-07-29 Allergan Inc PHARMACEUTICAL COMPOUNDS OF BOTULINIC TOXIN
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
JP4711520B2 (en) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 Bioactive peptide-containing powder
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US7820194B2 (en) * 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
SI21257A (en) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stable pharmaceutical preparation containing erythropoietin
CA2799413A1 (en) * 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20090324647A1 (en) * 2005-10-11 2009-12-31 Borodic Gary E Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
US20070154493A1 (en) * 2005-12-30 2007-07-05 Judy Hattendorf Method of treating skin needing botulinum toxin type a treatment
AU2010214834B2 (en) * 2009-02-19 2016-04-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
KR102328155B1 (en) * 2009-06-25 2021-11-17 레반스 테라퓨틱스, 아이엔씨. Albumin-free botulinum toxin formulations
KR101788340B1 (en) * 2009-10-21 2017-10-19 메르츠 파마 게엠베하 운트 코. 카가아 System for determining unprocessed and partially processed neurotoxin type a
WO2011088993A1 (en) * 2010-01-22 2011-07-28 Merz Pharma Gmbh & Co. Kgaa In vitro assay for quantifying clostridial neurotoxin activity
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
US20120201857A1 (en) * 2010-03-17 2012-08-09 Pankaj Modi Transdermal delivery system for therapeutics
CA2814054A1 (en) * 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
ES2810098T3 (en) * 2011-03-31 2021-03-08 Medy Tox Inc Botulinum toxin lyophilized preparation
EP2694975A1 (en) * 2011-04-08 2014-02-12 Biogen Idec MA Inc. Biomarkers predictive of therapeutic responsiveness to ifnbeta and uses thereof
JP6236332B2 (en) 2014-02-24 2017-11-22 ホシザキ株式会社 Refrigeration equipment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351162A1 (en) * 1988-07-11 1990-01-17 Albright & Wilson Limited Stabilised enzyme dispersion
JPH034791A (en) * 1989-05-30 1991-01-10 Kanebo Ltd Stabilization of enzyme
WO1997027841A1 (en) * 1996-01-31 1997-08-07 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
WO2000015245A2 (en) * 1998-09-11 2000-03-23 Elan Pharmaceuticals, Inc. Stable liquid formulations of botulinum toxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
WO2004060384A2 (en) * 2002-12-20 2004-07-22 Botulinum Toxin Research Associates, Inc. Pharmaceutical botulinum toxin compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOODMAN GREG: "Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis.", DERMATOLOGIC SURGERY : OFFICIAL PUBLICATION FOR AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY [ET AL.]. MAY 2003, vol. 29, no. 5, May 2003 (2003-05-01), pages 533 - 538 ; dis, XP002356481, ISSN: 1076-0512 *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 112 (C - 0815) 18 March 1991 (1991-03-18) *

Also Published As

Publication number Publication date
IL180771A0 (en) 2007-06-03
KR100852824B1 (en) 2008-08-18
ZA200700433B (en) 2008-07-30
ECSP077197A (en) 2007-04-26
CA2578250C (en) 2013-03-05
EP2266599B1 (en) 2014-04-16
KR20070028590A (en) 2007-03-12
CN101005853A (en) 2007-07-25
ES2479515T3 (en) 2014-07-24
US8652489B2 (en) 2014-02-18
EP2266599A3 (en) 2012-11-21
AU2005274822B2 (en) 2008-10-30
US20160074486A1 (en) 2016-03-17
EP2266599A2 (en) 2010-12-29
KR20080049152A (en) 2008-06-03
EP2266600A2 (en) 2010-12-29
EP2266600B1 (en) 2014-09-10
KR100852821B1 (en) 2008-08-18
IL180771A (en) 2014-09-30
EP1786459B1 (en) 2014-02-12
JP2013107904A (en) 2013-06-06
KR100852822B1 (en) 2008-08-18
AU2005274822A1 (en) 2006-02-23
BRPI0513850A (en) 2008-05-20
US20150231259A1 (en) 2015-08-20
US9220783B2 (en) 2015-12-29
CN101005853B (en) 2011-05-04
IL219897A0 (en) 2012-06-28
JP2008507581A (en) 2008-03-13
JP4907530B2 (en) 2012-03-28
US9050367B2 (en) 2015-06-09
EA200700213A1 (en) 2007-08-31
EA011652B1 (en) 2009-04-28
US20140105882A1 (en) 2014-04-17
US7879341B2 (en) 2011-02-01
NO20071043L (en) 2007-04-02
US10105421B2 (en) 2018-10-23
EP2266600A3 (en) 2012-11-21
US20130121987A1 (en) 2013-05-16
US8372645B2 (en) 2013-02-12
WO2006020208A2 (en) 2006-02-23
CA2799413A1 (en) 2006-02-23
EP1786459A2 (en) 2007-05-23
CA2578250A1 (en) 2006-02-23
HK1107670A1 (en) 2008-04-11
MX2007000794A (en) 2007-04-09
JP2011016846A (en) 2011-01-27
US20110091503A1 (en) 2011-04-21
US20060018931A1 (en) 2006-01-26
CN102139099A (en) 2011-08-03
IL225848A0 (en) 2013-06-27
KR20080050636A (en) 2008-06-09

Similar Documents

Publication Publication Date Title
WO2006020208A3 (en) Therapeutic composition whit a botulinum neurotoxin
WO2007044809A3 (en) Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
MX336807B (en) Compositions and methods for producing a composition.
WO2005100403A3 (en) Antibodies to erythropoietin receptor and uses thereof
BRPI0513327A (en) solid or liquid pharmaceutical composition comprising botulically neurotoxin
WO2007002465A3 (en) Stabilizing alkylglycoside compositions and methods thereof
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
ATE483027T1 (en) RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROKARYONTIC CELLS
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
WO2005113592A3 (en) Interferon-alpha polypeptides and conjugates
WO2008082889A3 (en) Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
MX2009003193A (en) Molecular switches and methods for their use.
PL1776137T3 (en) Pharmaceutical composition containing botulinum neurotoxin a2
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2004054607A3 (en) Stable therapeutic proteins
WO2008108808A3 (en) Complexes derived from heterohybrid cells and uses thereof
WO2006047728A3 (en) Bmp gene and fusion protein
WO2006000213A3 (en) Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2007134118A3 (en) Protein based composition and methods of using same
WO2006049983A3 (en) Peptide yy modified transferrin fusion proteins
WO2006035311A3 (en) Group a streptococcus crge protein
WO2001064876A3 (en) Human schizophrenia gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 30/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12007500080

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2578250

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007/00433

Country of ref document: ZA

Ref document number: 200700433

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005274822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 180771

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000794

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020077001912

Country of ref document: KR

Ref document number: 2007523628

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200700213

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005274822

Country of ref document: AU

Date of ref document: 20050719

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005274822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580028206.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005765454

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 07019089

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 1020077001912

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005765454

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513850

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 219897

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 225848

Country of ref document: IL